05.09.2023 • News
Lonza, Vertex Break Ground on New US Cell Therapy Plant
Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.
Contract Development And Manufacturing Organizations (CDMO)
29.08.2023 • News
EuroAPI to Acquire German CDMO BianoGMP
Active pharmaceutical ingredients manufacturer EuroAPI has agreed to acquire BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. Biano is to become a EuroAPI company but retain its corporate brand.
01.08.2023 • News
Finnish CDMO Biovian Expands its Facility in Turku
Finnish contract development and manufacturing organization (CDMO) Biovian, specializing in biopharmaceuticals, is investing more than €50 million to expand its manufacturing facility in Turku, Finland.
17.07.2023 • News
Upperton Completes Construction of New Development and Manufacturing Site
Upperton Pharma Solutions, a UK contract development and manufacturing organization (CDMO), has completed construction of its new development and GMP manufacturing headquarters in Nottingham, UK. The company said it has invested £15 million in the new 50,000-square-foot facility.
Expanding Expertise in Highly-Potent APIs
After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.
Increasing the Sustainability of API Production
For Siegfried, sustainability is much more than a phrase with a green coating. The term, which encompasses social and economic criteria in addition to ecological aspects, is one of five central corporate values. One of the biggest levers for reducing energy and resource consumption in the pharma supply chain lies in the efficient production of active ingredients and pharmaceuticals. The company therefore works consistently on optimizing its processes.
Small Substances with Big Effects
The market for APIs is expanding significantly. Experts predict annual growth rates between 4.5 and 7.6 percent by 2029. There are plenty of good reasons for this: Chronic diseases are on the rise - and with them the need for medicines and active ingredients. In addition, the economic upswing in several emerging countries means that more people can afford novel medicines. APIs are also benefiting from the trend toward personalized medicine and the growing understanding of diseases. Meanwhile, API developers and manufacturers are working on increasingly sophisticated methods to better handle these delicate substances.
Opportunities and Limits of Sustainability
The Pharmaceutical industry must prioritize sustainability. Jürgen Roos, Chief Scientific Officer (CSO) of Siegfried, explains opportunities and limits of sustainability.
Special Issue: Swiss CDMO Siegfried Celebrates 150th Anniversary
There are only a few chemical and pharmaceutical companies that look back at a history of 150 years. Certainly, many companies claim such a long legacy, but if you only count those that have been operating and thriving under the same name for a century and a half, the number boils down significantly.
Sustainability – The Many Facets of Action
Climate change, energy crisis, the call for a more environmentally compatible production method and socially responsible action do not stop at the pharmaceutical and biotech industries. Sustainability is becoming a central competitive and reputation factor and carries a high economic value. This need not be to the industry´s disadvantage. It helps companies to make processes more efficient, reduces energy consumption and keeps costs in check. But is the pharmaceutical industry already doing enough in this regard?
Siegfried Demonstrates Biologics Expertise in Hameln
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.
"We Want to Be a Big Fish"
The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.
26.05.2023 • News
Olon Expands API Production
Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi province.
04.05.2023 • News
CordenPharma Expands at US Site in Colorado
CordenPharma is expanding strategically into synthetic oligonucleotide manufacturing at its plant at Boulder in the US state of Colorado. The two-phase investment is designed to provide innovative biotech and pharma customers with a fully integrated API to Drug Product service offering.
13.04.2023 • News
WuXi STA Expands Capabilities at Changzhou Campus
WuXi STA has added two reactors at its Changzhou campus in China, enhancing capacity and capability at its TIDES contract research, development and manufacturing platform for oligonucleotide, peptide and related synthetic conjugates. The reactors have capacity of 2,000 liters each, taking total volume for solid-phase peptide synthesizers to more than 10,000 liters.
13.04.2023 • News
Catalent Starts Schorndorf Expansion
Catalent, a US-headquartered CDMO, has broken ground on a project in Schorndorf, Germany, that will add capacity for storing and handling clinical trial supply materials at controlled temperatures.
Delivering Quality with Speed for European Market
In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and the goals of the European expansion.
03.03.2023 • News
Aenova Appoints Hanno Scheffczik as Managing Director of its Marburg Site
Hanno Scheffczik has been appointed as the new Managing Director of Temmler Pharma, a member of the Aenova Group. Effective Mar. 1, 2023, he succeeds Alfred Veit, who is retiring.
22.02.2023 • Topics • Innovation
Axplora Aims to Make Pharmaceutical Supply Chains More Stable
Interview with Sylke Hassel, previous CEO of PharmaZell and current CEO of Axplora following the merger with Novasep.
20.02.2023 • News
Canada’s Biodextris Builds Biologics Facility
Canadian CDMO Biodextris plans to build a new industrial-scale vaccine and biologics facility in Laval, Quebec. The company said the cGMP biomanufacturing center and its analytical capabilities will be an asset in its development as a world-class CDMO.
13.02.2023 • News
Lotte Outlines Plans to Become Major CDMO Player
Lotte Biologics, part of South Korean conglomerate Lotte, has detailed expansions plans for the business as it embarks on a path to become a top 10 CDMO by 2030.
13.12.2022 • News
Catalent Opens Cell Therapy Facility in Belgium
Catalent has opened a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in Gosselies, Belgium.
07.12.2022 • News
Flow Chemistry
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
06.12.2022 • News
Catalent Completes Shanghai Plant Expansion
US-headquartered CDMO giant Catalent has completed the expansion of its clinical supply facility in the Waigaoqiao Free Trade Zone (FTZ) in Shanghai, China.
10.11.2022 • News
Change of Ownership for US CDMO Alcami
UK specialist healthcare investor GHO Capital Partners and US investment firm The Vistria Group have entered into an agreement to buy a controlling interest in US CDMO Alcami from current private equity owners Madison Dearborn Partners (MDP) and Ampersand Capital Partners. Financial terms of the deal were not disclosed.
02.11.2022 • News
Curia Begins Work on New Mexico Expansion
US CDMO Curia has begun construction on an expansion of its campus in Albuquerque, New Mexico. The facility designed by Burns & McDonnell will be built by BE&K Building Group.
31.10.2022 • News
Recipharm Bolsters Blow-Fill-Seal Capabilities in France
Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated technology.
27.10.2022 • News
Symeres Strengthens US Foothold with Exemplify Buy
Dutch CDMO Symeres has acquired Exemplify Biopharma, a US-based contract research organization (CRO) based in Cranbury, New Jersey, USA. The deal further strengthens Symeres’ foothold in the US, where it already generates about 50% of its revenues.
26.10.2022 • News
Catalent to Invest $12 Million at Kansas City
Catalent has announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.
The Future of Outsourcing
The increasing complexity in drug development and the highly competitive industry landscape are creating a dramatic shift in how pharmaceutical and biotech companies plan for and execute drug development and production.
Investing in Growth Through Innovation
Interview with Marc Doyle, CEO of Arxada, which was created following the carve-out and sale of Lonza Specialty Ingredients to private equity firms Bain Capital and Cinven.
14.10.2022 • News
CDMO Adragos to Buy Sanofi Site in Japan
Munich-based German CDMO Adragos Pharma said it has signed a definitive agreement with Sanofi’s Japanese subsidiary to acquire a pharmaceutical manufacturing site in Kawagoe, near Tokyo.
14.10.2022 • News • Innovation
Bachem Innovates its Manufacturing Capabilities
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.
Ensuring API Supply Capacities for Europe and Beyond
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
23.09.2022 • News
Olon Expands Indian API Capabilities
Italian API producer Olon has announced plans to install a new high-containment production line at its site in Mahad, India.
Frost & Sullivan
PP Consulting
Informa Markets
Cambrex Corporation
Syngene International Ltd.
Resilience
Suanfarma
Alcami Corporation
Gallus Biopharmaceuticals, LLC
Sanner GmbH
Fujifilm
Global Gateway Advisors
FDA Smart
Arthur D. Little
Axplora
DCAT - Drug, Chemical & Associated Technologies Association
GLSyntech LLC
Siegfried
Ferak Berlin GmbH
Aenova Holding GmbH
HAS Healthcare Advanced Synthesis SA
Lonza AG
IDT Biologika GmbH
Curia
Patheon Italia
WeylChem International GmbH
Haltermann Ltd.
Catalent Inc.
CHEManager International c/o Wiley-VCH GmbH
Saltigo GmbH
Veranova
Society of Chemical Manufacturers & Affiliates (SOCMA)
DSM Pharmaceutical Products
Kurma Partners
Quotient Sciences
Alira Health S.r.l.
CPA Chemical Pharmac. Ass.
Ofichem Group
Olon S.p.A.
Bachem
Mabion
CatSci Ltd.
Camelot Management Consultants AG
Ardena
AmbioPharm, Inc.
Asahi Kasei Europe
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Rentschler Biopharma SE
Mack Brooks Exhibition Ltd – Part of RX
WittKiefer